Publications by authors named "C Michael Zwaan"
Background: The effect of age on doxorubicin pharmacokinetics remains inconclusive, especially in patients at the extremes of the age spectrum. We developed a population pharmacokinetic model to further investigate the impact of age on the pharmacokinetics of doxorubicin.
Methods: A three-compartment model, incorporating allometric scaling was developed to describe doxorubicin pharmacokinetics across all ages.
Background: Acute myeloid leukemia (AML) is a heterogenous and complex blood cancer requiring aggressive treatment. Early identification and prediction of the complications following treatment is vital for effective disease management.
Aims: We explored associations between plasma protein levels and fever- and infection-related complications in 26 AML patients during chemotherapy-induced neutropenia.
Article Synopsis
- Acute myeloid leukemia (AML) is a serious blood cancer with a complex genetic background, particularly affecting children through specific gene rearrangements associated with poor treatment outcomes.
- * In AML, translocations involving the NUP98 gene create fusion proteins that disrupt normal cell functions, leading to abnormal cell growth and structure.
- * This review explores the roles of NUP98 fusion proteins in AML and discusses potential new treatment strategies targeting these specific genetic alterations.
Because of the low mutational burden and consequently, fewer potential neoantigens, children with acute myeloid leukemia (AML) are thought to have a T cell-depleted or 'cold' tumor microenvironment and may have a low likelihood of response to T cell-directed immunotherapies. Understanding the composition, phenotype, and spatial organization of T cells and other microenvironmental populations in the pediatric AML bone marrow (BM) is essential for informing future immunotherapeutic trials about targetable immune-evasion mechanisms specific to pediatric AML. Here, we conducted a multidimensional analysis of the tumor immune microenvironment in pediatric AML and non-leukemic controls.
View Article and Find Full Text PDFArticle Synopsis
- Aberrant expression of HOX and MEIS1 family genes in certain leukemias disrupts normal blood cell differentiation and contributes to leukemia development.
- Menin inhibitors can target the interaction between KMT2A and menin, reducing the abnormal expression of key factors and promoting differentiation in these leukemias.
- A collaborative effort among pediatric and adult specialists aims to advance menin inhibitors in treatment, offering a comprehensive overview of clinical trials and advocating for inclusive trial designs for youth.